MF
BPMC

Magnetar Financial’s Blueprint Medicines BPMC Stock Holding History

Magnetar Financial’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-730,047
Closed -$93.6M – 913
2025
Q2 		$93.6M Buy
730,047
+725,479
+15,882% +$75.4M 0.45% 4
2025
Q1 		$404K Buy
4,568
+1,484
+48% +$145K 0.01% 506
2024
Q4 		$269K Buy
+3,084
New +$282K 0.01% 498
2023
Q2 		– Sell
-9,266
Closed -$417K – 498
2023
Q1 		$417K Sell
9,266
-1,862
-17% -$83.9K 0.01% 476
2022
Q4 		$488K Buy
+11,128
New +$534K 0.01% 606
2022
Q2 		– Sell
-13,781
Closed -$880K – 1679
2022
Q1 		$880K Buy
+13,781
New +$989K 0.01% 820
2021
Q3 		– Sell
-6,454
Closed -$568 – 1322
2021
Q2 		$568 Buy
+6,454
New +$591K 0.01% 850

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Magnetar Financial's BPMC Position: Q3 2025 in Review

Magnetar Financial sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 730,047 shares — an estimated $93.6M sold.

Magnetar Financial first reported a position in BPMC in Q2 2021 and held it in 7 quarters. The position peaked at $93.6M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Magnetar Financial reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Magnetar Financial sold 730,047 Blueprint Medicines shares in Q3 2025, an estimated $93.6M.
  • Magnetar Financial first reported a position in Blueprint Medicines in Q2 2021 and held it in 7 quarters.
  • Magnetar Financial's Blueprint Medicines position peaked at $93.6M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Magnetar Financial's 13F filing for Q3 2025, filed 13 Nov 2025.